Literature DB >> 27746204

COUNTERPOINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? No.

Peter J Barnes1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27746204     DOI： 10.1016/j.chest.2016.09.023

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  4 in total

1.  Daily dose of itraconazole 100 mg to treat allergic bronchopulmonary aspergillosis (ABPA) related eosinophilia: a case report.

Authors:  A E Konstantinou; E Christaki; C Pitsios
Journal:  Hippokratia       Date:  2017 Jul-Sep       Impact factor: 0.471

2.  Nonadherence in the era of severe asthma biologics and thermoplasty.

Authors:  Joy Lee; Tunn Ren Tay; Naghmeh Radhakrishna; Fiona Hore-Lacy; Anna Mackay; Ryan Hoy; Eli Dabscheck; Robyn O'Hehir; Mark Hew
Journal:  Eur Respir J       Date:  2018-04-04       Impact factor: 16.671

3.  The Role of Access and Cost-Effectiveness in Managing Asthma: A Systematic Review.

Authors:  Christopher D Codispoti; Matthew Greenhawt; John Oppenheimer
Journal:  J Allergy Clin Immunol Pract       Date:  2022-05-05

4.  Sub-stratification of type-2 high airway disease for therapeutic decision-making: A 'bomb' (blood eosinophils) meets 'magnet' (FeNO) framework.

Authors:  Simon Couillard; Ian D Pavord; Liam G Heaney; Nayia Petousi; Timothy S C Hinks
Journal:  Respirology       Date:  2022-05-19       Impact factor: 6.175
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.